Novel Multimodal Salicylamide Derivative with Antidepressant-like, Anxiolytic-like, Antipsychotic-like, and Anti-Amnesic Activity in Mice

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 2; p. 175
• Main Authors: Żmudzka, Elżbieta, Lustyk, Klaudia, Głuch-Lutwin, Monika, Wolak, Małgorzata, Jaśkowska, Jolanta, Kołaczkowski, Marcin, Sapa, Jacek, Pytka, Karolina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.01.2023; MDPI
• Subjects: Amphetamines; anti-amnesic effect; Antianxiety agents; antidepressant-like activity; Antidepressants; Antipsychotic drugs; antipsychotic-like properties; Antipsychotics; Anxiety; anxiolytic-like action; Chemical properties; Dopamine; Drug dosages; Drug therapy; Memory; memory-enhancing; Mental depression; Mental disorders; Mental health; Motor ability; Psychotropic drugs; Retention; Salicylic acid; Schizophrenia; Serotonin; serotonin receptor antagonist; Statistical analysis; Structure; Swimming; Testing; Poland; antipsychotic-like properties; serotonin receptor antagonist; antidepressant-like activity; anti-amnesic effect; memory-enhancing; anxiolytic-like action
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16020175

Depression, anxiety, and schizophrenia may coexist in psychiatric patients. Moreover, these disorders are very often associated with cognitive impairments. However, pharmacotherapy of these conditions remains challenging due to limited drug effectiveness or numerous side effects. Therefore, there is an urgent need to develop novel multimodal compounds that can be used to treat depression, anxiety, and schizophrenia, as well as memory deficits. Thus, this study aimed to evaluate the potential antidepressant-like, anxiolytic-like, antipsychotic-like effects, and anti-amnesic properties, of the novel arylpiperazine derivative of salicylamide, JJGW07, with an affinity towards serotonin 5-HT , 5-HT , and 5-HT and dopamine D receptors. Firstly, we investigated the compound's affinity for 5-HT receptors and its functional activity by using in vitro assays. JJGW07 did not bind to 5-HT receptors and showed antagonistic properties for 5-HT , 5-HT , 5-HT , and D receptors. Based on the receptor profile, we performed behavioral studies in mice to evaluate the antidepressant-like, anxiolytic-like, and antipsychotic-like activity of the tested compound using forced swim and tail suspension tests; four-plate, marble-burying, and elevated plus maze tests; and MK-801- and amphetamine-induced hyperlocomotion tests, respectively. JJGW07 revealed antidepressant-like properties in the tail suspension test, anxiolytic-like effects in the four-plate and marble-burying tests, and antipsychotic-like activity in the MK-801-induced hyperlocomotion test. Importantly, the tested compound did not induce catalepsy and motor impairments or influence locomotor activity in rodents. Finally, to assess the potential procognitive and anti-amnesic properties of JJGW07, we used passive avoidance and object recognition tests in mice. JJGW07 demonstrated positive effects on long-term emotional memory and also ameliorated MK-801-induced emotional memory impairments in mice, but showed no procognitive properties in the case of recognition memory. Our results encourage the search for new compounds among salicylamide derivatives, which could be model structures with multitarget mechanisms of action that could be used in psychiatric disorder therapy.